Kairos Pharma, LTD S-1 registration statements

Kairos Pharma is registering shares for resale by Helena Global Investment Opportunities I Ltd., potentially raising up to $15 million through an equity line of credit agreement.

Kairos Pharma has filed a registration statement for the resale of 6.4 million shares of common stock, including shares underlying warrants issued in a recent private placement.

Kairos Pharma updates its IPO registration statement, detailing officer loan conversions to common stock and ongoing clinical trial funding.

Kairos Pharma, a clinical-stage biopharmaceutical company, is seeking to raise $6.2 million through an initial public offering to advance its cancer therapeutics pipeline and list its stock on the NYSE American under the symbol KAPA.

Kairos Pharma, a clinical-stage biopharmaceutical company, is seeking to raise $6.2 million through an initial public offering to advance its cancer therapeutics pipeline.

Kairos Pharma aims to raise capital through an initial public offering to fund clinical trials and further develop its pipeline of cancer therapeutics.

Kairos Pharma, a clinical-stage biopharmaceutical company, is seeking to raise $6.2 million through an initial public offering to advance its cancer therapeutics pipeline and list its common stock on the NYSE American under the symbol KAPA.

Kairos Pharma details the terms and conditions for common stock purchase warrants, including exercise price, expiration date, and transfer restrictions, in its latest S-1/A filing.

Clinical-stage biopharmaceutical company Kairos Pharma, Ltd. has filed an amendment to its Form S-1 registration statement with the SEC, seeking to raise $6.2 million in an initial public offering.